IRWD Q1 2024 Earnings — Ironwood Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IRWDIronwood Pharmaceuticals, Inc.

$629M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$75M-28.0% YoY

Gross Profit

$49M65.5% margin

Operating Income

$11M14.7% margin

Net Income

-$4M-5.6% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

-36.3%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$45M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$439M

Total Liabilities

$769M

Stockholders' Equity

-$331M

Cash & Equivalents

$122M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$104M	-28.0%
Gross Profit	$49M	$104M	-52.7%
Operating Income	$11M	$60M	-81.7%
Net Income	-$4M	$46M	-109.1%

Revenue Segments

Collaborative arrangement, other agreements

$516,00058%

Collaborative arrangement, collaboration and license agreements

$368,00042%

Geographic Segments

North America

$72M99%

Europe and Other

$706,0001%